8158 (8158) Fair Value & Analysis

Healthcare · Market cap HK$85.2M

8 8158 8158 · HK

PriceHK$0.2800

Fair ValueHK$0.7900

Upside+182.1%

Quality46/100

Watch 8158 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.6200 – HK$0.9900

Fair value as of: Jul 2, 2026

From 23 valuation models · updated today

Share price −27.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2410 – HK$0.9700 · fair‑value band HK$0.6200 – HK$0.9900 · the HK$0.2800 price screens below the HK$0.7900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8158 (8158) currently trades at HK$0.2800, while our model-based Fair Value estimate is HK$0.7900 — implying the stock looks roughly 182.1% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 8158 generated revenue of HK$72.1M at a net margin of 38.2%. Revenue grew 44.9% year over year. It earns a return on equity of 70.0%. Net debt stands at HK$43.1M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$72.1M

Revenue growth (YoY) +44.9%

Net margin 38.2%

Return on equity 70.0%

Free cash flow HK$4.0M FY2025

P/E ratio 3.1

More key figures

Operating margin 5.9%

EPS (TTM) HK$0.0200

EPS growth (YoY) +2,411%

Net debt HK$43.1M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8158 reported revenue of HK$72.1M in FY2025 versus HK$283M in FY2021, a compound −29.0%/yr. Reported net income was HK$27.5M in FY2025, compounding −14.6%/yr from FY2021.

Revenue −29.0%/yr

FY21 HK$283M

FY22 HK$41.5M

FY23 HK$69.5M

FY24 HK$90.6M

FY25 HK$72.1M

Net income −14.6%/yr

FY21 HK$51.8M

FY22 HK$4.6M

FY23 −HK$108M

FY24 HK$17.8M

FY25 HK$27.5M

Is 8158 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	449.62 MXN	-94%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€274.90	€211.40	-23%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$291.22	$111.44	-62%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8158 (8158) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.7900 versus a price of HK$0.2800 — about +182% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 8158?

Our model-based fair value for 8158 is HK$0.7900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2800.

What is the quality score of 8158?

8158 has a Quality Score of 46/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8158 (8158)?

8158 reported trailing-twelve-month revenue of about HK$72.1M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 8158?

The net profit margin of 8158 is about 38.2%, meaning it keeps roughly 38.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.